Aqtual, Inc., a pioneering biotech company based in Hayward, California, has announced a major milestone: the successful close of its $31 million Series B funding round. Led by CEO and co-founder Diana Abdueva, Aqtual is on a mission to transform how autoimmune diseases are treated, offering hope to millions who struggle daily with chronic conditions.

This Series B round was supported by leading investors including Bold Capital, BOLD Longevity Growth Fund, Genoa Ventures, Manta Ray Ventures, Yu Galaxy, and others. Their support highlights strong confidence in Aqtual’s innovative approach and its potential to reshape the future of immunotherapy.

A New Approach to Autoimmune Diseases

More than 50 million Americans suffer from autoimmune diseases such as rheumatoid arthritis, lupus, and multiple sclerosis. Current treatments focus on suppressing the entire immune system, often leaving patients vulnerable to infections and other complications.

Aqtual’s approach is radically different. Instead of blanket suppression, the company’s proprietary platform recalibrates specific immune cells responsible for attacking healthy tissues. This method promises to correct harmful immune responses while preserving overall immune function - a true leap forward in precision medicine.

Under the leadership of Diana Abdueva, Aqtual has shown promising preclinical results. Their strategy directly targets the root cause of autoimmunity, rather than merely masking symptoms, and could set a new standard in treatment protocols worldwide.

Redefining What’s Possible

What truly sets Aqtual apart is its bold willingness to question entrenched norms. In the autoimmune space, the prevailing belief has long been that widespread immune suppression is the only feasible option. Diana Abdueva and her team challenged this head-on, asking: What if we could correct the immune system’s behavior without shutting it down entirely?

By addressing this core question, Aqtual is moving the narrative from reactive disease management to proactive immune re-education. This insight offers a powerful lesson for other founders: transformative breakthroughs often emerge when you dismantle "accepted" limitations in your industry. Instead of working around systemic problems, solving them at the root level can transform your solution from “nice to have” into an indispensable, category-defining innovation.

Aqtual’s commitment to going deeper - beyond symptomatic relief to address the immune system's core dysfunction - exemplifies what it means to create true value in a crowded market. For founders, the takeaway is clear: the biggest opportunities lie not in incremental improvements, but in reimagining what your users believe is possible.

Expanding Impact and Global Potential

With the new funding, Aqtual plans to accelerate preclinical studies, strengthen its research and development capabilities, and prepare for future clinical trials. The company also aims to build advanced manufacturing and data infrastructure to support scaling and ensure consistent, high-quality therapeutic production.

This work could have far-reaching impacts beyond rheumatoid arthritis. Aqtual’s platform has potential applications in other chronic inflammatory conditions, representing a new frontier in autoimmune disease treatment.

The startup's strategic location in Hayward, California - part of the San Francisco Bay Area's vibrant biotech ecosystem - provides access to world-class research talent and partnerships with top academic institutions.

Delivering Real Hope to Patients

For patients living with autoimmune diseases, Aqtual’s progress represents more than a scientific advance - it’s a lifeline. The potential to live free from constant flares and dependence on harsh immunosuppressive drugs is life-changing.

The psychological relief of reclaiming daily activities without fear of unpredictable setbacks cannot be overstated. Aqtual’s approach promises to restore not just physical health but also independence, confidence, and emotional well-being.

Looking Ahead

Aqtual’s $31 million Series B marks a major leap forward in its mission to redefine what’s possible in autoimmune therapy. With Diana Abdueva at the helm, the company is well-positioned to lead a new era in precision immunology, challenging outdated assumptions and delivering transformative impact on a global scale.

As the biotech world watches closely, Aqtual stands as a shining example of what can happen when visionary leadership, deep science, and patient-centered innovation come together. For founders in every industry, the message is clear: true market-shaping solutions are born from tackling the problems everyone else accepts as "unsolvable."